| OMIDENEPAG ISOPROPYL | None | ||
| 0.002 |
Less Than $1000 mn
|
||
| None | None | ||
| None | None | ||
| None | None | ||
| Omlonti (omidenepag isopropyl ophthalmic solution) 0.002%, is a relatively selective prostaglandin E2 (EP2) receptor agonist, indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. | |||
|
Yes
| |||
| OMLONTI | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| *** ********* | |||||||||||||
| ****************** **** ******** | ******* *********** *** ********* ** *********** ** ******** | ************** ************ ********** * ****************** **** ******** | ************** ************ ********** * ****************** **** ******** | ************** ************ ********** * ****************** **** ******** | ************** *********** ********** ****************** **** ******** | ******* ** *-*********** *********** ******** | ************** ************ ********** * ****************** **** ******** | ************** *********** ********** ******* *********** **** ******** | ************** ************ ********** * ****************** **** ******** | ************** *********** ********** ******* *********** **** ******** | ************** ************ ********** * ****************** **** ******** | ************** ************ ********** * ****************** **** ******** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|